Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Biocon

What Is The Impact Of Rupee Appreciation On Pharma & InfoTech Stocks & Should We Buy Them? Daljeet Kohli



The appreciation in the value of the INR vis-à-vis the USD has caused Pharma & InfoTech stocks to under-perform the Index. Daljeet Kohli explains the extent of the impact and offers valuable advice on what investors should do

Did You Know That Mutual Funds Are Giving 45+% Annual Gain?



It is astonishing that several diversified small-cap and mid-cap mutual funds have given incredible annual returns of upto 48%. How have they achieved this feat?

Time To Take Your Money Off The Table And Run: Ashwani Gujral



Ashwani Gujral has given sensible advice that investors should take advantage of the rally to book some profits and park it for deployment when the market crashes

Ashwani Gujral’s Top Mid-Cap Stock Picks For 2014



Ashwani Gujral is a veteran stock trader who has a number of good stock calls to his credit. He says that Mid-caps are coming out of a bear phase and the time is ripe to buy them. He reveals his top stock picks for 2014

Top 10 Mid-cap Stock Ideas From IIFL For 2014



IIFL has released a report in which it has identified stocks with good fundamentals and reasonable valuations which are expected to do well in the medium to long-term

Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!